European Union awards InterAx with Horizon 2020 SME Instrument
Villigen – Switzerland, Brussels – Belgium, July 2018 Villigen
InterAx Biotech AG today announces the support of the highly competitive European Union’s Horizon 2020 research and innovation program for Small to Medium-Sized Enterprise (SME) for the development of its discovery platform. The InterAx technology integrates in vitro and computational pharmacology for smart drug candidate design and selection. In phase 1, InterAx is awarded EUR 50'000 and mentored by EU industry experts to compile a feasibility study for a phase 2 proposal (EUR 0.5-2.5 Mio). The team thanks the European Commission for the trust received.
The European Union’s Horizon 2020 research and innovation program supports breakthrough innovation projects with a market-creating potential. The SME instrument boosts fast company growth and market-creating innovation thanks to staged funding and ramped up business acceleration services.